[video+transcript]Gene Therapy Could Be a Boon for This Biotech

[video+transcript]Gene Therapy Could Be a Boon for This Biotech

Source: 
Motley Fool
snippet: 

In this clip from The Motley Fool's Industry Focus: Healthcare, host Shannon Jones is joined by Motley Fool contributor Todd Campbell to discuss how Regenxbio's proprietary viral vectors could present investors with an opportunity to profit from treatments for spinal muscular atrophy and wet age-related macular degeneration, two blockbuster indications.